Answers are grounded in this paper and cite their sources.
B-enriched l-BPA-based dipeptides as next-generation boron delivery agents. These dipeptides, incorporating hydrophilic peptide linkages, enabled substantially higher intravenous bolus doses in mice compared to l-BPA while maintaining favorable biodistribution. In vivo, the dipeptides were rapidly cleaved by endogenous proteases, releasing l-BPA de novo within tumors. Neutron irradiation of syngeneic CT26 tumors in dipeptide-treated mice produced complete and durable tumor regressions, accompanied by immunological effects including a vaccine response and abscopal tumor suppression. By contrast, l-BPA administered at its solubility-limited maximal dose under the same irradiation conditions produced only a transient tumor growth delay, without durable regression or evidence of immune activation. These findings establish the dipeptides as prodrugs that overcome the solubility limitations of l-BPA, enabling higher-dose administration with improved tumor control and immune-mediated benefits. This strategy has the potential to expand patient management options and enhance the therapeutic impact of BNCT.
No takes yet. Share an insight, caveat, or question.
Torgov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: